Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Exametazime→

Exametazime Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
105613-48-7
Molecular formula
C13H28N4O2
Molecular weight
272.39 g/mol
Drug class
Technetium-99m exametazime (HMPAO)diagnostic radiopharmaceutical tracer
Mechanism of action
Lipophilic 99mTc-labelled complex crosses cell membranes and is retained intracellularly after conversion to a more hydrophilic form. Distribution reflects regional perfusion or labelled leukocyte localisation, depending on the prepared product.
Indications / reported uses
  • Diagnostic SPECT imaging of regional cerebral perfusion using 99mTc-exametazime prepared for brain imaging
  • In-vitro radiolabelling of autologous leukocytes with 99mTc-exametazime for imaging suspected infection or inflammation; these are distinct preparation and use pathways

Sources: NLM MeSH — Technetium Tc 99m exametazime · PubMed — 99mTc-HMPAO leukocyte and cerebral perfusion imaging · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Exametazime Environmental Risk Assessment (ERA) (the Exametazime ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.